

Proj. Ref. No. BAC4-21-033-B

End-User Property and Supply Division

Project SUPPLY & DELIVERY OF VARIOUS DRUGS AND MEDICINES (TABLETS/ORAL SOLID)  
FOR CY 2022 (FRAMEWORK AGREEMENT)

Opening of Bids: **11 January 2022**

ITEM NO.	QTY	UNIT	ITEM DESCRIPTION	ABC PER UNIT (PHP)	QUOTATIONS (all taxes included)	
					in figures	in words
73	6,860	Pc.	Acetazolamide 250mg tablet	20.00		
74	564	Pc.	Aciclovir 200mg tablet	8.80		
75	425	Pc.	Aciclovir 800mg tablet	63.70		
76	378	Pc.	Alendronate sodium 70mg tablet	175.09		
77	6,278	Pc.	Allopurinol 100mg tablet	4.35		
78	5,579	Pc.	Allopurinol 300mg tablet	9.25		
79	2,100	Pc.	Amiodarone Hydrochloride 200mg tablet	35.50		
80	72,800	Pc.	Amlodipine besilate/camsylate 10mg tablet	6.00		
81	67,831	Pc.	Amlodipine besilate/camsylate 5mg tablet	2.68		
82	360	Pc.	Aripiprazole 10mg tablet	216.48		
83	500	Pc.	Aspirin 100mg tablet	2.75		
84	130	Pc.	Atenolol 100mg tablet	3.20		
85	132	Pc.	Atenolol 50mg tablet	3.37		
86	1,315	Pc.	Azathioprine 50mg tablet	34.30		
87	5,000	Pc.	Baclofen 10mg tablet	15.50		
88	128	Pc.	Betahistine (as hydrochloride/dihydrochloride) 24mg tablet	54.00		
89	320	Pc.	Betahistine (as hydrochloride/dihydrochloride) 8mg tablet	20.00		
90	1,986	Pc.	Biperiden Hydrochloride 2mg tablet	18.50		
91	4,820	Pc.	Bisacodyl 5mg tablet	5.90		
92	860	Pc.	Bisoprolol fumarate 2.5mg tablet	21.31		
93	780	Pc.	Bisoprolol fumarate 5mg tablet	15.67		
94	6,100	Pc.	Calcitriol 0.25mcg capsule	20.00		
95	27,690	Pc.	Calcium carbonate + cholecalciferol Vitamin D3 (equivalent to 600mg elemental calcium + 400 IU Vit D3) tablet	4.60		
96	26,440	Pc.	Calcium carbonate tablet/chewable tablet (equiv to 500mg elemental calcium)	6.50		
97	6,320	Pc.	Captopril 25mg tablet	3.30		

Proj. Ref. No. BAC4-21-033-B

End-User Property and Supply Division

Opening of Bids: **11 January 2022**

Project SUPPLY &amp; DELIVERY OF VARIOUS DRUGS AND MEDICINES (TABLETS/ORAL SOLID)

FOR CY 2022 (FRAMEWORK AGREEMENT)

98	500	Pc.	Cefixime 400mg capsule	134.00		
99	230	Pc.	Chlorpromazine Hydrochloride 100mg tablet	12.80		
100	100	Pc.	Chlorpromazine Hydrochloride 200mg tablet	68.89		
101	2,550	Pc.	Ciclosporin 100mg capsule	259.75		
102	1,670	Pc.	Ciclosporin 25mg capsule	64.50		
103	150	Pc.	Cinnarizine 25mg tablet	1.50		
104	5,812	Pc.	Ciprofloxacin Hydrochloride 500mg tablet	19.35		
105	945	Pc.	Clarithromycin 500mg base tablet	19.20		
106	500	Pc.	Clonazepam 2 mg tablet	9.00		
107	1,360	Pc.	Clonidine Hydrochloride 150mcg tablet	40.19		
108	2,450	Pc.	Cloxacillin sodium 500mg capsule	4.35		
109	7,200	Pc.	Cotrimoxazole (sulfamethoxazole + trimethoprim) 400mg sulfamethoxazole + 80mg trimethoprim tablet/capsule	1.00		
110	30	Pc.	Danazol 200mg capsule	215.00		
111	2,560	Pc.	Deferasirox 250mg dispersable tablet	493.40		
112	720	Pc.	Deferiprone 500 mg tablet	105.97		
113	750	Pc.	Desmopressin acetate 100mcg tablet	124.75		
114	48,628	Pc.	Dexamethasone 4mg tablet	21.70		
115	111	Pc.	Diclofenac 50 mg tablet/capsule (as sodium or potassium salt)	2.85		
116	1,600	Pc.	Digoxin 250 micrograms tablet	5.00		
117	360	Pc.	Diltiazem Hydrochloride 60mg tablet	36.99		
118	2,528	Pc.	Diphenhydramine Hydrochloride 25mg capsule	10.00		
119	2,562	Pc.	Diphenhydramine Hydrochloride 50mg capsule	3.48		
120	3,928	Pc.	Divalproex Sodium or Sodium Valproate + Valporic Acid 250mg tablet	8.88		
121	9,350	Pc.	Domperidone 10mg tablet	16.50		
122	7,560	Pc.	Doxycycline hyclate 100mg capsule	14.75		

Proj. Ref. No. BAC4-21-033-B

End-User Property and Supply Division

Opening of Bids: **11 January 2022**

Project SUPPLY &amp; DELIVERY OF VARIOUS DRUGS AND MEDICINES (TABLETS/ORAL SOLID)

FOR CY 2022 (FRAMEWORK AGREEMENT)

123	385	Pc.	Dydrogesterone 10mg tablet	72.66		
124	2,596	Pc.	Enalapril maleate 20mg tablet	9.60		
125	37,740	Pc.	Enalapril maleate 5mg tablet	8.70		
126	60	Pc.	Entecavir 500 mcg tablet/ film-coated tablet	130.00		
127	1,030	Pc.	Erythromycin stearate 500 mg tablet	5.00		
128	12,500	Pc.	Escitalopram oxalate 10 mg tablet	21.83		
129	1,210	Pc.	Ethambutol hydrochloride 400 mg tablet	3.50		
130	737	Pc.	Famotidine 20mg tablet	24.75		
131	560	Pc.	Felodipine 5mg MR tablet	12.00		
132	300	Pc.	Felodipine 10mg MR tablet	30.25		
133	290	Pc.	Fenofibrate 160 mg tablet	29.80		
134	480	Pc.	Fenofibrate 200mg capsule	26.78		
135	1,564	Pc.	Finasteride 5mg tablet	18.00		
136	4,840	Pc.	Fluconazole 150mg capsule	184.62		
137	4,180	Pc.	Fluconazole 200mg capsule	500.00		
138	6,200	Pc.	Fluconazole 50mg capsule	85.00		
139	100	Pc.	Flutamide 250mg tablet	65.00		
140	4,800	Pc.	Furosemide 20mg tablet	1.30		
141	4,900	Pc.	Furosemide 40mg tablet	1.90		
142	3,480	Pc.	Gabapentin 100mg capsule	25.00		
143	5,471	Pc.	Gabapentin 300mg capsule	15.00		
144	3,043	Pc.	Gliclazide 60 mg MR tablet	20.00		
145	1,997	Pc.	Gliclazide 80 mg tablet	7.30		
146	835	Pc.	Haloperidol 5 mg tablet	23.78		

Proj. Ref. No. BAC4-21-033-B

End-User Property and Supply Division

Opening of Bids: **11 January 2022**

Project SUPPLY &amp; DELIVERY OF VARIOUS DRUGS AND MEDICINES (TABLETS/ORAL SOLID)

FOR CY 2022 (FRAMEWORK AGREEMENT)

147	810	Pc.	Hydrochlorothiazide 25mg tablet	3.15		
148	1,010	Pc.	Hydroxychloroquine sulfate 200mg tablet	77.20		
149	6,760	Pc.	Hydroxyurea 500mg capsule	16.25		
150	100	Pc.	Hydroxyzine dihydrochloride 25 mg tablet	65.00		
151	3,974	Pc.	Hyoscine N-butyl bromide 10mg tablet	5.75		
152	1,350	Pc.	Ibuprofen 200 mg tablet	1.75		
153	2,300	Pc.	Irbesartan 150mg tablet	3.77		
154	100	Pc.	Irbesartan + Hydrochlorothiazide 150 mg irbesartan + 12.5 mg hydrochlorothiazide tablet	9.88		
155	310	Pc.	Isoniazid 300 mg tablet	0.83		
156	20,160	Pc.	Isoniazid/Rifampicin/Pyrazinamide/Ethambutol 75mg/150mg/400mg/275mg tablet	9.00		
157	15,520	Pc.	Isoniazid + Rifampicin + Ethambutol 75 mg + 150 mg + 275 mg tablet	15.18		
158	1,030	Pc.	Isosorbide dinitrate 10mg tablet	19.05		
159	2,240	Pc.	Isosorbide dinitrate 5mg sublingual tablet	20.83		
160	730	Pc.	Isoxsuprine hydrochloride 10mg tablet	19.50		
161	300	Pc.	Itraconazole 100mg capsule	65.00		
162	421	Pc.	Lagundi 600mg tablet	4.15		
163	250	Pc.	Lamotrigine 100mg tablet	17.00		
164	530	Pc.	Lansoprazole 30 mg capsule	20.90		
165	23,907	Pc.	Levetiracetam 500 mg film coated tablet	23.50		
166	3,817	Pc.	Levodopa + Carbidopa 100 mg levodopa + 25 mg carbidopa per tablet	21.50		
167	5,034	Pc.	Levodopa + Carbidopa 250 mg levodopa + 25 mg carbidopa per tablet	35.00		
168	360	Pc.	Linezolid 600 mg tablet/film-coated tablet	3,750.00		
169	2,410	Pc.	Lithium carbonate 450mg MR tablet	4.76		
170	7,761	Pc.	Loperamide Hydrochloride 2mg capsule	3.00		
171	37,482	Pc.	Losartan potassium 100mg tablet	8.00		

Proj. Ref. No. BAC4-21-033-B

End-User Property and Supply Division

Opening of Bids: **11 January 2022**

Project SUPPLY &amp; DELIVERY OF VARIOUS DRUGS AND MEDICINES (TABLETS/ORAL SOLID)

FOR CY 2022 (FRAMEWORK AGREEMENT)

172	87,706	Pc.	Losartan potassium 50mg tablet	7.00		
173	18,649	Pc.	Losartan + Hydrochlorothiazide 50 mg losartan + 12.5 mg hydrochlorothiazide tablet	12.00		
174	1,100	Pc.	Mebendazole 500mg tablet/chewable tablet	4.00		
175	600	Pc.	Mecobalamin 500 microgram tablet	13.67		
176	2,400	Pc.	Memantine 10 mg film coated tablet	18.00		
177	1,000	Pc.	Medroxyprogesterone 10mg tablet (as acetate)	85.50		
178	1,604	Pc.	Methimazole (thiamazole) 5mg tablet	5.41		
179	1,400	Pc.	Methyldopa 250mg tablet	11.00		
180	493	Pc.	Montelukast sodium 5mg chewable tablet	17.50		
181	12,083	Pc.	Morphine sulfate 10mg tablet/capsule (With PDEA Permit)	40.50		
182	1,260	Pc.	Moxifloxacin 400mg film coated tablet	103.67		
183	300	Pc.	Multivitamins Adult (per tablet/capsule) Composition: Vitamin A - 600 – 700 mcg or 2,000 – 2,500 IU Vitamin B1 - 1.3 – 1.7 mg Vitamin B2 - 0.7 - 1.3 mg Vitamin B6 - 1.6 – 2 mg Vitamin B12 - 2 -6 mcg Vitamin C - 60 - 80 mg Vitamin D - 400 IU (10 mcg) Vitamin E - 6 – 10 mg (15 – 30 IU) Folic Acid - 400 mcg Niacin - 13 – 23 mg	4.25		
184	3,710	Pc.	Mycophenolate mofetil 500mg tablet	56.00		
185	600	Pc.	Mycophenolic acid(Mycophenolate sodium) 360mg tablet	58.71		
186	702	Pc.	Naproxen sodium 250 mg base (275 mg) tablet	7.29		
187	466	Pc.	Naproxen sodium 500 mg base (550 mg) tablet	3.38		
188	1,200	Pc.	Nifedipine 10 mg capsule	4.90		
189	11,400	Pc.	Nimodipine 30mg tablet	27.52		
190	1,300	Pc.	Nitrofurantoin 100 mg capsule (as macrocrystals)	18.00		
191	9,100	Pc.	Ondansetron Hydrochloride dihydrate 8mg tablet	95.00		

Proj. Ref. No. BAC4-21-033-B

End-User Property and Supply Division

Opening of Bids: **11 January 2022**

Project SUPPLY &amp; DELIVERY OF VARIOUS DRUGS AND MEDICINES (TABLETS/ORAL SOLID)

FOR CY 2022 (FRAMEWORK AGREEMENT)

192	680	Pc.	Pantoprazole 40 mg tablet/enteric-coated tablet	35.00		
193	1,500	Pc.	Phenobarbital 15 mg tablet	2.75		
194	1,500	Pc.	Phenobarbital 30 mg tablet	8.68		
195	1,500	Pc.	Phenobarbital 60 mg tablet	5.20		
196	1,500	Pc.	Phenobarbital 90 mg tablet	5.35		
197	330	Pc.	Phenoxymethyl Penicillin (penicillin V) (as potassium salt) 250 mg tablet/capsule	11.75		
198	300	Pc.	Phenoxymethyl Penicillin (penicillin V) (as potassium salt) 500 mg tablet/capsule	19.75		
199	460	Pc.	Phenytoin sodium 100mg capsule	31.46		
200	33,749	Pc.	Potassium chloride 750mg durules (as chloride) equiv. to approximately 10mEq potassium	23.00		
201	31,445	Pc.	Prednisone 20mg tablet	7.00		
202	29,339	Pc.	Prednisone 5mg tablet	1.90		
203	10,935	Pc.	Propranolol Hydrochloride 10mg tablet	9.44		
204	5,385	Pc.	Propranolol Hydrochloride 40mg tablet	30.00		
205	9,700	Pc.	Propylthiouracil 50mg tablet	27.80		
206	62,604	Pc.	Pyridostigmine bromide 60mg tablet	29.61		
207	3,000	Pc.	Quetiapine (as fumarate) 300mg tablet	52.85		
208	10,568	Pc.	Ranitidine Hydrochloride 150mg tablet	0.88		
209	11,745	Pc.	Sacubitril/Valsartan 50 mg tablet	56.25		
210	10,532	Pc.	Sacubitril/Valsartan 100 mg tablet	56.25		
211	5,951	Pc.	Sambong [Blumea balsamifera (L) DC (Fam. Compositae)] 500mg tablet	6.85		
212	5,768	Pc.	Sertraline Hydrochloride 50mg tablet	38.00		
213	68,121	Pc.	Sevelamer Carbonate 800mg tablet	34.63		
214	9,354	Pc.	Simvastatin 20mg tablet	5.50		
215	4,113	Pc.	Simvastatin 40mg tablet	8.00		

Proj. Ref. No. BAC4-21-033-B

End-User Property and Supply Division

Opening of Bids: **11 January 2022**

Project SUPPLY &amp; DELIVERY OF VARIOUS DRUGS AND MEDICINES (TABLETS/ORAL SOLID)

FOR CY 2022 (FRAMEWORK AGREEMENT)

216	51,600	Pc.	Sodium Bicarbonate 650 mg tablet	5.25		
217	9,800	Pc.	Spironolactone (K-sparer) 100mg tablet	33.00		
218	11,747	Pc.	Spironolactone (K-sparer) 25mg tablet	15.00		
219	12,700	Pc.	Spironolactone (K-sparer) 50mg tablet	36.28		
220	5,000	Pc.	Standard Senna Concentrate 187mg tablet	9.06		
221	4,800	Pc.	Standard Senna Concentrate 374mg tablet	19.50		
222	2,450	Pc.	Sucralfate 1g tablet	45.00		
223	2,631	Pc.	Tacrolimus 1mg capsule	85.00		
224	2,800	Pc.	Tamsulosin 200 mcg orally disintegrating tablet	38.49		
225	1,800	Pc.	Telmisartan + Hydrochlorothiazide 40 mg + 12.5 mg tablet	23.15		
226	1,860	Pc.	Tenofovir alafenamide fumarate 25 mg tablet	70.00		
227	1,510	Pc.	Terazosin (as hydrochloride) 1mg tablet	51.00		
228	4,830	Pc.	Terazosin (as hydrochloride) 2mg tablet	23.00		
229	11,940	Pc.	Terazosin (as hydrochloride) 5mg tablet	173.87		
230	2,760	Pc.	Tolvaptan 15 mg tablet	693.75		
231	1,600	Pc.	Topiramate 50mg tablet	9.25		
232	3,700	Pc.	Tramadol Hydrochloride 100 mg MR tablet	79.90		
233	20,140	Pc.	Tranexamic acid 500mg tablet/capsule	15.00		
234	360	Pc.	Valganciclovir 450mg tablet	1,498.17		
235	100	Pc.	Valsartan 160mg tablet/film-coated tablet	11.23		
236	2,450	Pc.	Verapamil hydrochloride 80 mg tablet	53.14		
237	544	Pc.	Voriconazole 200 mg film-coated tablet	1,000.00		
238	1,210	Pc.	Warfarin (as sodium salt) 1mg tablet	17.63		
239	1,855	Pc.	Warfarin (as sodium salt) 2.5mg tablet	19.50		
240	1,312	Pc.	Warfarin (as sodium salt) 5mg tablet	325.00		
<b>TOTAL APPROVED BUDGET FOR THE CONTRACT: PhP32,699,378.35</b>						

Proj. Ref. No. BAC4-21-033-B  
End-User Property and Supply Division  
Project SUPPLY & DELIVERY OF VARIOUS DRUGS AND MEDICINES (TABLETS/ORAL SOLID)  
FOR CY 2022 (FRAMEWORK AGREEMENT)

Opening of Bids: **11 January 2022**

Approved by:

  
Dean VICENTE Y. BELIZARIO, JR., M.D.  
Chairperson

\_\_\_\_\_  
(Signature over Printed Name of President/Gen. Manager)

\_\_\_\_\_  
(Name & Address of Company)

**TERMS & CONDITIONS FOR THE SUPPLY AND DELIVERY OF VARIOUS  
DRUGS AND MEDICINES (AMPULES/VIALS) FOR CY 2022 (FRAMEWORK AGREEMENT)**

- 1 Indicate the **brand and packing of the item/s** offered.
- 2 The brand offered must be **at least five (5) years commercially available in the market from date of opening of bids**. Proof of this shall be the initial Certificate of Product Registration (CPR) issued by the Food and Drug Administration (FDA).
- 3 **Submit the following documents, submission should be per product, with tab and per item number. Two (2) copies for the Valid Certificate of Product Registration and Certificate of Analysis (COA).**
  - a. **Memorandum of Agreement (MOA) and Certificate of exclusive/ authorized distributorship between the manufacturer and distributor.**

Distributors/suppliers must have certification from their principals that they are the exclusive distributor of the drug products authorized to submit tender for the product on behalf of the principal and that all commitments made by them shall be honored by the principal in case of termination of distributorship agreement.
  - b. **Valid Certificate of Product Registration (CPR)** issued by the Food and Drug Administration (FDA).
    - **The name of the respective distributor should appear on the submitted CPR of the drug.**

*Note: CPRs that will expire within three (3) months from the date of opening of bids should present the Official Receipt of renewal of application with the Document Tracking log for the CPR from the FDA.*
  - c. **Certificate of Analysis (COA)** for the products offered (batch to be delivered if awarded) duly issued by an FDA accredited laboratory (local) and should contain information indicated in monograph of the drug. Sample analyzed must not be expired during the time of bidding. The result of assay submitted must be in the specific brand and should be in the exact dosage formulation of the drug being bidded. In cases where local laboratories are unavailable to perform drug assays, assays done abroad is accepted. The local COA is preferred and given more weight in the evaluation and awarding process.
  - d. **A notarized certificate** that it is the innovator drug (if applicable).



Proj. Ref. No. BAC4-21-033-B

End-User Property and Supply Division

Project SUPPLY & DELIVERY OF VARIOUS DRUGS AND MEDICINES (TABLETS/ORAL SOLID)  
FOR CY 2022 (FRAMEWORK AGREEMENT)

Opening of Bids: 11 January 2022

- e. **Certificate of Good Manufacturing Process (CGMP).**
  - f. **Valid License to Operate (LTO).**
  - g. **A notarized certificate that the offered brand has not been subject to product complaint/product recall** for the past three (3) years.
  - h. **Certificate of Acceptance** from at least three (3) major hospitals issued within the year and should be supported with Sales Invoice (*for new item/brand offered only*).
  - i. **A notarized certificate** that there are sufficient stocks for the offered item/s for one (1) year.
- 4 The offered drug must conform to the latest Philippine Food and Drug Administration (FDA) Administrative Order **governing the generic labeling and packaging requirements.**
- 4.1 For all tablets and capsules**
- 4.1.1 **All tablets/capsules should be in foil or blister pack. A picture of the blister pack (front and back) should be submitted.**
  - 4.1.2 Each individual flap in the tablet or capsule blister pack should be labeled with the generic name and brand.
  - 4.1.3 Dosage form and strength of the Active Pharmaceutical Ingredients (API) should appear on each unit or every 2 units for products with multiple APIs.
  - 4.1.4 Name of drug, lot or batch number and expiry date must appear on every standard blister pack/foil strip and on the container or inner packing. However, if the product is not restricted for dispensing in quantities less than the standard blister pack or foil strip, the batch or lot number and expiry date should appear on each unit.
  - 4.1.5 Inner label must be the same as the outer label.
  - 4.1.6 A complete drug literature/product insert must accompany the product.
- 5 The following must be complied with specific for **inhalation anesthetics and cytotoxic injectable drugs.**
- 5.1 For inhalation anesthetics**
- 5.1.1 Submit **certification from the bidder that inhalation bottle must be with safety sealed cap**, airtight and capable to dispense directly from bottle the possibility of ambient air coming into contact with agent to prevent contamination and spillage.
  - 5.1.2 Submit **certification from the bidder that product container or anesthetic agent is shatterproof and transparent for visual check of content.** Container material must ensure stability of the agent to prevent degradation, must not be easy to break.
  - 5.1.3 Winning bidder for Sevoflurane shall *provide at least thirty-five (35) vaporizers* on loan and in good working conditions until the validity of the contract.
- 5.2 For Cytotoxic Injectable Drugs**

Proj. Ref. No. BAC4-21-033-B

End-User Property and Supply Division

Project SUPPLY & DELIVERY OF VARIOUS DRUGS AND MEDICINES (TABLETS/ORAL SOLID)  
FOR CY 2022 (FRAMEWORK AGREEMENT)

Opening of Bids: 11 January 2022

5.2.1 For cytotoxic injectable drugs, winning bidders are required to provide *Material Safety Data Sheet (MSDS)* and to submit *Drug Profile* to the Pharmacy Department per company under the first Purchase Order.

5.2.2 Winning bidders for cytotoxic injectable drugs are required to **provide at least three (3) spill kits** per company under the first Purchase Order.

5.2.3 For Paclitaxel, a special IV set must be provided per unit of the drug.

6 **New brands offered** shall be subject to further evaluation and shall require the following:

- a. Validation of the submitted Certificate of Acceptance from at least three (3) major hospitals;
- b. Justification from end-user/s to validate the acceptance of the good/s offered (to be facilitated by PGH-PSD).

7 **For the supply and delivery of awarded drugs and medicines.**

7.1 Delivery of the goods is required as stated in the request of the end-user, commencing on the 3rd working day of notification through confirmed fax/email that the approved Call-off/ Notice to Supplier (NTS) is already available for pick up.

7.2 Delivery schedule (whichever is applicable):

- a) within seven (7) calendar days
- b) as may be called for;
- c) staggered delivery within three (3) months
  - \* 50% of the total quantity within seven (7) calendar days and 25% each for the succeeding months

*Note: The end-user has the right to adjust the quantity to be delivered depending on the actual need of the hospital*

7.3 Deliveries shall have **at least two (2) years expiration date**.

7.4 Delivery of goods **with product complaint shall be put on hold** until receipt of the final decision of the PGH management whether to proceed with the acceptance or to cancel/return the items.

7.5 Delivered **items found to be non-formulary at any given time shall be returned** to the company and a credit memo shall be issued.

7.6 Stocks delivered **are subject to random sampling for testing** as to quality and conformity to label. Testing fee at supplier's expense.

7.7 Stocks with lot #/batch different from the submitted Certificate of Analysis (COA) will be subjected to testing as to quality and conformity to label. Testing fee at supplier's expense.

7.8 All items that had been pulled out for various reasons, a credit memo shall be issued by the Contractor within one (1) month, otherwise, a debit memo shall be processed by UP Manila - PGH and the amount will be deducted from any amount due to Supplier.

7.9 It is understood that the Supplier is legally responsible to deliver all

**Proj. Ref. No.** BAC4-21-033-B

**End-User** Property and Supply Division

**Project** SUPPLY & DELIVERY OF VARIOUS DRUGS AND MEDICINES (TABLETS/ORAL SOLID)  
FOR CY 2022 (FRAMEWORK AGREEMENT)

**Opening of Bids:** 11 January 2022

issued **CALL-OFF/s** (Purchase Order) and **failure to deliver the first Call-Off as scheduled shall mean automatic cancellation of the Call-Off and Notice to Execute Framework Agreement (NEFA).**

Purchase from other source for whatever means shall be effected immediately to provide the requirements of the hospital. Penalty to the defaulting contractor shall be charged accordingly.

- 8 **Failure to comply with the submission of the required documents shall be ground for post-disqualification in accordance with RA 9184.**
- 9 Compliance with RA 9184 and other applicable laws.

Approved by:



Dean VICENTE Y. BELIZARIO, JR., M.D.  
Chairperson

---

(Signature over Printed Name of President/Gen. Manager)

---

(Name & Address of Company)